Item 7.01 Regulation FD Disclosure.

As previously disclosed, on January 13, 2009, officers of Humana Inc. (the "Company") will be meeting with investors and analysts at an industry conference. During the meetings, the Company intends to address its prospects and performance and will reaffirm the Company's earnings per share guidance for the full year 2008 of $3.80 to $3.90, and for the full year 2009 of $5.90 to $6.10. In addition, the Company expects gross sales for Medicare Advantage for 2009 to be higher than previously forecast, while gross sales for stand-alone Prescription Drug Plans are expected to be in line with previous projections. The Company is continuing to receive January 2009 disenrollment data for all Medicare plans from the Centers for Medicare and Medicaid Services ("CMS"), consistent with historical disenrollment reporting patterns from CMS. Initial data indicates higher attrition than previously forecast in both Medicare Advantage and stand-alone Prescription Drug Plans. For 2009, the Company still anticipates net additions of 25,000 to 75,000 members to its Medicare Advantage program, but expects the decline in membership in the Company's stand-alone Prescription Drug Plans to be higher than previously forecast.

---